Clinical Trials Directory

An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

This is a long-term safety extension study of IDELA (idelalisib) in subjects with hematologic malignancies who complete other IDELA studies. Subjects will be followed according to the standard of care as appropriate for their type of cancer, and will be treated at the dosage level received upon completion of their prior IDELA study. Subjects will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to IDELA, or if they no longer derive clinical benefit in the opinion of the investigator

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Idelalisib

Phase: Phase 1

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients with hematologic malignancies completing a prior idelalisib study with a clinical benefit are eligible - Women of childbearing potential must have a negative pregnancy test to be eligible - Male patients, and female patients of childbearing potential, must agree to use method(s) of contraception specified in the protocol

External Links

Footer Links: